Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Clinical Outcome
19 results:

  • 1. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without kdr mutation: A case report.
    Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
    Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-vegfr2 cancer therapy.
    Jung K; Heishi T; Khan OF; Kowalski PS; Incio J; Rahbari NN; Chung E; Clark JW; Willett CG; Luster AD; Yun SH; Langer R; Anderson DG; Padera TP; Jain RK; Fukumura D
    J Clin Invest; 2017 Aug; 127(8):3039-3051. PubMed ID: 28691930
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis.
    Wang L; Sun Y; Zhao B; Zhang H; Yu Q; Yuan X
    Oncotarget; 2016 Aug; 7(34):55732-55740. PubMed ID: 27248177
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.
    Giampieri R; Salvatore L; Del Prete M; Prochilo T; D'Anzeo M; Loretelli C; Loupakis F; Aprile G; Maccaroni E; Andrikou K; Bianconi M; Bittoni A; Faloppi L; Demurtas L; Montironi R; Scarpelli M; Falcone A; Zaniboni A; Scartozzi M; Cascinu S
    Sci Rep; 2016 Apr; 6():25195. PubMed ID: 27117754
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
    Sole CV; Calvo FA; Alvarez E; Carreras JL
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1444-52. PubMed ID: 26883667
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Proteins of the vegfr and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
    Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
    J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
    Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
    Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Personalizing therapy for colorectal cancer.
    Wong A; Ma BB
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):139-44. PubMed ID: 24025538
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prospective validation of candidate SNPs of VEGF/vegfr pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. clinical significance of vegfr-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
    Sole CV; Calvo FA; Alvarez E; Peligros I; Garcia-Alfonso P; Ferrer C; Ochoa E; Herranz R; Carreras JL
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1635-44. PubMed ID: 23801169
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PDGFRα/β and vegfr2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
    Estevez-Garcia P; Castaño A; Martin AC; Lopez-Rios F; Iglesias J; Muñoz-Galván S; Lopez-Calderero I; Molina-Pinelo S; Pastor MD; Carnero A; Paz-Ares L; Garcia-Carbonero R
    BMC Cancer; 2012 Nov; 12():514. PubMed ID: 23146028
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
    Zhang W; Azuma M; Lurje G; Gordon MA; Yang D; Pohl A; Ning Y; Bohanes P; Gerger A; Winder T; Hollywood E; Danenberg KD; Saltz L; Lenz HJ
    Anticancer Res; 2010 Oct; 30(10):4209-17. PubMed ID: 21036743
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer.
    Eppenberger M; Zlobec I; Baumhoer D; Terracciano L; Lugli A
    BMC Cancer; 2010 Mar; 10():93. PubMed ID: 20222950
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
    Tsirlis TD; Papastratis G; Masselou K; Tsigris C; Papachristodoulou A; Kostakis A; Nikiteas NI
    World J Gastroenterol; 2008 May; 14(17):2691-701. PubMed ID: 18461654
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.